Trastuzumab after primary treatment for early stage HER2-positive breast cancer reduces recurrence

被引：3
|
作者：
Dent, R [1 ]
Clemons, M [1 ]
机构：
[1] Sunnybrook & Womens Coll, Hlth Sci Ctr, Div Med Oncol, Toronto, ON M4N 3M5, Canada
来源：
CANCER TREATMENT REVIEWS | 2006年 / 32卷 / 02期
关键词：
D O I：
10.1016/j.ctrv.2006.01.005
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：144 / 148
页数：5
相关论文
共 50 条
  • [1] Role of trastuzumab in the adjuvant treatment of HER2-positive early breast cancer
    Haq, Bushra
    Geyer, Charles E.
    WOMENS HEALTH, 2009, 5 (02) : 135 - 147
  • [2] Risk of Recurrence in Early-Stage, HER2-Positive Breast Cancer
    Isaacs, Claudine
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (08) : 3 - 6
  • [3] Neratinib for the treatment of HER2-positive early stage breast cancer
    Echavarria, Isabel
    Lopez-Tarruella, Sara
    Marquez-Rodas, Ivan
    Jerez, Yolanda
    Martin, Miguel
    EXPERT REVIEW OF ANTICANCER THERAPY, 2017, 17 (08) : 669 - 679
  • [4] Personalized treatment for early stage HER2-positive breast cancer
    Prat, A.
    CANCER RESEARCH, 2021, 81 (04)
  • [5] Optimal treatment of early stage HER2-positive breast cancer
    Pernas, Sonia
    Barroso-Sousa, Romualdo
    Tolaney, Sara M.
    CANCER, 2018, 124 (23) : 4455 - 4466
  • [6] Spotlight on trastuzumab in the management of HER2-positive metastatic and early-stage breast cancer
    Plosker, Greg L.
    Keam, Susan J.
    BIODRUGS, 2006, 20 (04) : 259 - 262
  • [7] Spotlight on Trastuzumab in the Management of HER2-Positive Metastatic and Early-Stage Breast Cancer
    Greg L. Plosker
    Susan J. Keam
    BioDrugs, 2006, 20 : 259 - 262
  • [8] Trastuzumab and Vinorelbine in Early Stages of HER2-Positive Breast Cancer
    Ferrario, C.
    Wong, A.
    Gao, T.
    Bouganim, N.
    Aloyz, R.
    Panasci, L. C.
    JOURNAL OF CHEMOTHERAPY, 2011, 23 (01) : 32 - 35
  • [9] Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
    von Minckwitz, Gunter
    Procter, Marion
    de Azambuja, Evandro
    Zardavas, Dimitrios
    Benyunes, Mark
    Viale, Giuseppe
    Suter, Thomas
    Arahmani, Amal
    Rouchet, Nathalie
    Clark, Emma
    Knott, Adam
    Lang, Istvan
    Levy, Christelle
    Yardley, Denise A.
    Bines, Jose
    Gelber, Richard D.
    Piccart, Martine
    Baselga, Jose
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (02): : 122 - 131
  • [10] Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer
    Douchet, G.
    Richard, Sandrine
    ONCOLOGIE, 2018, 20 (01) : 43 - 44
12345